| Literature DB >> 34222199 |
Tanumoy Sarkar1, Monikha Chetia1, Sunanda Chatterjee1.
Abstract
Rapid rise of antimicrobial resistance against conventional antimicrobials, resurgence of multidrug resistant microbes and the slowdown in the development of new classes of antimicrobials, necessitates the urgent development of alternate classes of therapeutic molecules. AntimicrobialEntities:
Keywords: AMP delivery strategies; antimicrobial activity; antimicrobial peptides; antimicrobial resistance; cytotoxicity; natural and synthetic AMPs; protease resistance
Year: 2021 PMID: 34222199 PMCID: PMC8249576 DOI: 10.3389/fchem.2021.691532
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
FIGURE 1Classification of AMPs based on their structures. (A) α-helical AMPs: (i) Magainin (PDB code—2LSA), (ii) Cecropin (PDB code—2LA2). (B) β-sheet AMPs: (i) Bovine Lactoferrin (PDB code—1LFC), (ii) Hepcidin (PDB code—2KEF), (iii) Rabbit Kidney Defensins (PDB code—1EWS). (C) α-helix, β-sheet mixed AMPs: RNase 2 (PDB code—1GQV). (D) Random coil structure of AMPs: Cys deleted protein (PDB code—2MQ5).
Natural antimicrobial peptides (aa = amino acid; res = residues).
| Name of the AMPs | Natural source | Physicochemical properties | Structure | Activity | References |
|---|---|---|---|---|---|
| Natural cationic antimicrobial peptides | |||||
| α Defensins | Mammals including humans, monkeys; several rodent species; plants | Cationic; three disulfide bridges; Mol wt.: 3–4 kDa | Triple-stranded β- sheet | Antiviral, virucidal, antifungal |
|
| Anticancer activity (HNP1,2,3), chemotactic activity | |||||
| β Defensins | Almost all mammals, insects, plants | Cationic; three disulfide bridges; Mol wt.: 2–6 kDa | β- sheet | Virucidal, anticancer activity (hBD1), chemotactic activity |
|
| Cathelicidin LL-37 | Humans | 37 aa res; Cationic Sequence: LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | α-helical Three parts: N- and C-terminal α-helices (2–30 aa res.), unstructured C-terminal tail (31–37 aa res) | Virucidal, antifungal antiparasitic activity, anticancer activity, chemotactic activity, apoptosis, wound healing |
|
| Hepcidin 25 (LEAP-1) | Humans | Four disulfide bridges; Sequence - DTHFPICIFCCGCCHRSKCGMCCKT (Disulfide bridges: 7–23, 10–13, 11–19, 14–22) | β- sheet | Antifungal activity, active against gram-positive and gram-negative bacteria |
|
| RNase 2 (EDN) | Humans (in large specific granules of human eosinophilic leukocytes) | Cationic; also called eosinophil derived neurotoxin (EDN); Non-secretory ribonuclease; Mol. Wt. ∼ 18 kDa | α,β-mixed structure | Antiviral activity, antiparasitic activity |
|
| RNase 3 (ECP) | Humans (in the eosinophil primary matrix) | Cationic; also known as eosinophil cationic protein (ECP) Mol. Wt.: 18–22 kDa | α,β-mixed structure | Antiviral activity, Antiparasitic activity |
|
| Lysozyme | Found in most mammals including humans; Bacteria, funci | Positively charged enzymes; aa res > 100 | Structure comprising of large number of α-helices, β-sheet and random coils | Catalyzes the hydrolysis of 1,4-β-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidoglycan, which is the major component of gram-positive bacterial cell wall |
|
| Thionins | Plants | Contains 45–47 amino acids and are usually high in cyst, lysine, and arginine; highly charged and basic; Mol. Wt.: ∼5 kDa | α,β-mixed structure | Bacteria, Fungi, yeast |
|
| Cecropins | Insects; first isolated from the hemolymph of | 31–39 aa res; Cationic Cecropin A: KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK; Cecropin B: KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL; Cecropin P1: SWLSKTAKKLENSAKKRISEGIAIAIQGGPR | α-helical | Broad-spectrum activity against gram-positive and gram-negative bacteria, fungi |
|
| Mellitin | Constitutes 40–60% of dry honeybee (Apis mellifera) venom | 26 aa res; Cationic; Sequence; GIGAVLKVLTTGLPALISWIKRKRQQ-NH2 | α-helical in the presence of membrane mimics | Acts by inserting itself across the phospholipid bilayer, and interact between biomembrane and proteins; Antibacterial, anti-inflammatory; Effective against MRSA |
|
| Jelleines | Isolated from the western honey bee or European honey bee (Apis mellifera) | 8–9 aa res; Sequences: Jelleine-I (PFKLSLHL-NH2), jelleine-II (TPFKLSLHL-NH2), jelleine-III (EPFKLSLHL-NH2) and jelleine-IV (TPFKLSLH-NH2) | - | Active against yeast, fungi, gram-positive and gram-negative bacteria |
|
| Esculatin 1a | Skin of frogs ( | Sequence–H2N-GIFSKLAGKKIKNLLISGLKNVGKEVGMDVVRTGIDIAGCKIKGEC-COOH | Disordered in solution but adopts an α-helical structure when associated with the membranes mimics | Broad-spectrum antimicrobial activities against gram-positive and gram-negative bacteria |
|
| Esculatin 1b | Skin of frogs ( | Sequence–H2N-GIFSKLAGKKLKNLLISGLKNVGKEVGMDVVRTGIDIAGCKIKGEC-COOH | Disordered in solution but adopts an α-helical structure when associated with the membranes mimics | Broad-spectrum antimicrobial activities against gram-positive and gram-negative bacteria |
|
| Esculatin-2CHa | Skin of frogs ( | 37 aa res; Cationic Sequence: GFSSIFRGVAKFASKGLGK DLAKLGVDLVACKISKQC | α-helical | Broad-spectrum antimicrobial activities, Type 2 Diabetes |
|
| Temporins | Isolated from the skin secretion of European red frog ( | 10–14 aa res; Cationic Temporin A: FLPLIGRVLSGIL-NH2; Temporin B: LLPIVGNLLKSLL-NH2; Temporin C: LLPILGNLLNGLL-NH2; Temporin D: VLPIIGNLLNSLL-NH2; Temporin E: VLPIIGNLLNSLL-NH2; Temporin F: FLPLIGKVLSGIL-NH2; Temporin G: FFPVIGRILNGIL-NH2 Temporin H: LSP---NLLKSLL-NH2: Temporin K: LLP---NLLKSLL-NH2; Temporin L: FVQWESKFLGRIL-NH2 | α-helical | Gram-positive bacteria, MRSA, vancomycin resistant enterococcus faecium, enterococcus faecalis |
|
| Nigrocin 1 and 2 | Isolated from the Korean frog ( | Cationic; Gly rich; one disulfide bridge | Amphipathic α-helix in microbial membrane mimics | Broad-spectrum antimicrobial, gram-positive and gram-negative bacteria, protozoa and fungi |
|
| Buforin II | Isolated from the stomach tissue of Asian toad ( | 21 aa res; Pro hinge important for activity | α-helical | Broad-spectrum antimicrobial, non-membranolytic, affinity for DNA, RNA |
|
| Natural cyclic peptides | |||||
| Syringomycins |
| Cyclic lipopeptides; Lipodepsinona-peptide comprising of a closed ring of nine non-ribosomally synthesized aa res bonded to a | Combination of a lipid and a peptide. Peptide portion containing amino acids in a cycle. Some of the amino acids are rare, e.g. in Syringomycin-E: 2,4-diaminobutyric acid and β-hydroxy aspartic acid | Active against gram-positive bacteria, mycelia |
|
| Massetolide A | Pseudomonas fluorescence SS101 | Cyclic lipopeptide; consists of a 9-amino-acid cyclic oligopeptide linked to 3-hydroxydecanoic acid | Consists of a 9-amino-acid cyclic oligopeptide linked to 3-hydroxydecanoic acid | Affects plant pathogenic oomecytes |
|
| Amphisin | Pseudomonas sp. strain DSS73 | Cyclic lipoundeca-peptide; Amphiphilic having biosurfactant properties; Sequence: β-hydroxydecanoyl-DL-DD-D-allo-T-DL-DL-DS-LL-D-Q-LL-LI-LD. | The peptide is a lactone, linking Thr3 Oγ to the C-terminal.Helical structure (310-helix) | Antagonistic against oomycete |
|
| Lokisin | Pseudomonas sp. strain DSS41 | Cyclic lipoundeca-peptide; Leu rich having a D/L leu ratio of 3:2 Sequence: β-hydroxydecanoyl -DL-DD-D-allo-T-DL-DL-DS-LL-DS-LL-LI-LD. | The peptide is a lactone, linking Thr3 Oγ to the C-terminal- | Antagonistic against oomycete |
|
| Tensin |
| Cyclo Lipopeptide: Amphiphilic having biosurfactant properties; Sequence: β-hydroxydecanoyl- | The peptide is a lactone linking the Thr3 Oγ atom to the C-terminal C atom. Helical structure (310-helix) | Antagonistic against |
|
| Viscosinamide |
| Cyclo Lipopeptide; Depsipeptide having biosurfactant properties | Cyclized via an ester bond between the C-terminal carbonyl and the side chain of a D-allo-Thr at position 3, leading to a 7-residue macrocycle | Antagonistic against oomycete |
|
| Iturins |
| Cyclic lipopeptide Nonribosomal lipopeptide family of seven residues of α and β aa res | Peptide ring of seven aa res including an invariable D-Tyr2, with the constant chiral sequence LDDLLDL closed by a C14-C17 aliphatic β aa | Exhibit strong antifungal activities against a wide variety of pathogenic yeasts and fungi; Shows selective antibacterial activity |
|
| Fengycins |
| Cyclic lipopeptides 10-aa res; β-hydroxy fatty acid | The structure is com-posed of a β-hydroxy fatty acid linked to a peptide part comprising 10 aa, where 8 of them are organized in a cyclic structure | Prevents growth of mycelia of |
|
| Surfactins |
| Cyclic lipopeptides; 7 aa res; β-hydroxy fatty acid of variable length; Amphipathic; Consists of a peptide loop of seven amino acids (LE-LL- DL,-LV,-LD-DL-LL) and a β-hydroxy fatty acid of variable length, thirteen to fifteen carbon atoms long | ‘Horse saddle’ conformation in solution | Antimicrobial against |
|
| Balliomycin D |
| 7 aa res; β-amino fatty acids with 14–16 C atoms | The lipid moiety consists of 3-amino-12-methyltridecanoic acid or 3-amino-12-methyltetradecanoic acid; the peptide moiety contains one residue of each of the following seven amino acid: DN-LD-LE-LP-DS-LT-DY | Inhibits |
|
| Mycosubtilin |
| Iturin derivative; 7 aa res; β-amino fatty acids with 14–16 C atoms | Mycosubtilin is a heptapeptide, cyclized in a ring with a β-amino fatty acid. The peptide sequence is composed of LN-DY-DN-LQ-LP-DS-LD | Strong antifungal activity |
|
| Fusaridins |
| Cyclic lipopeptides Group of depsipeptides with an unusual fatty acid, 15-guanidino-3-hydroxypentadecanoic acid moiety bound to a free amino group | - | Controls Phytopthora blight infection in red pepper caused by |
|
| Gramicidin S |
| Cyclicdeca-peptide; Composed of five different amino acids, each one used twice within the ring structure. Sequence: cyclo-(DPhe-Pro-Val-Orn-Leu)2 | C2-symmetric β-sheet structure that is stabilized by four interstrand hydrogen bonds between the Leu and Val residues | Antifungal activity and sporicidal activity |
|
| Valinomycin |
| Cyclopeptide Cyclic | Made of twelve alternating D- and L-aas and esters: D- and L-Val, D-α-hydroxyisovaleric acid, and L-lactic acid to form a macrocyclic molecule | Insecticidal, acaricidal, antifungal antioomecyte activity. Modulates the transport of potassium ions across biological membranes |
|
| Polyoxins |
| Cyclopeptide; nucleoside-peptide antibiotics | Polyoxin are pyrimidine nucleosides linked to a peptide moiety | Competitive inhibitors of chitin synthase |
|
| Arthrichitin |
| Cyclic depsipeptide; Consists of serine, β-keto tryptophan, glutamic acid, and 2,4-dimethyl-3-hydroxydodecanoic acid units Sequence: Cyclo (3-hydroxy-2,4-dimethyldodecanoyl-L-alpha-glutamyl-beta- oxotryptophyl-L-seryl) | - | Inhibits chitin biosynthesis/anti-fungal |
|
| Neopeptins |
| Cyclic lipopeptides; Nonadepsi-peptide; 9 unnatural aa res and an acyl chain | Cyclic; unusual structure and a varying lipid tail | Antifungal. Completely inhibits |
|
| Tyrocidins | Soil bacteria | Cyclic decapeptides rich in Phe; Sequence: Tyrocidine A: cyclo (LN-LQ-LW-LV-LOrn-LL-DF-LP-LF-DF). Tyrocidines B–D are isoforms of tyrocidine A with specific replacements of one (Tyrocidine B, L-Phe→ L-Trp at position 3), two (Tyrocidine C, L–Trp→L–Phe and D–Trp→D–Phe at positions 3 and 4), or three amino acid residues (Tyrocidine D, the changes observed in tyrocidine C in addition to L–Trp→L–Tyr at position 7) | Cyclic, Homodectic | Broad-spectrum anti-fungal activity |
|
| Aureobasidins |
| Cyclic depsipeptide; 8 lipophilic aa res, 1 α-hydroxy acid | Cyclic depsipeptide consisting of eight α aa units and one hydroxy acid unit. Sequence: 2(R)-hydroxy-3(R)-methylpentanoic acid, β-hydroxy-N-methyl-LV, N-methyl-LV-LP-allo-LI-N-methyl-LF-LL-LF. | Antifungal and antiprotozoal |
|
| Cyclotides | Plant | 28–37 aa res; head to tail cyclization; three disulfide bridges | Having a head-to-tail cyclic backbone and three conserved disulfide bonds that form a CCK motif | Anti-HIV, incesticidal, antimicrobial |
|
| Kalata B8 | Oldenlandia affinis | 31 aa res; Sequence: GSVLNCGETCLLGTCYTTGCTCNKYRVCTKD | Kalata B8 contains the CCK motif characteristic of cyclotides but has some interesting differences, including disordered loops 1 and 6 (of a total of 6 loops) | Uterotonic, anti-HIV, antimicrobial, insecticidal, antihelmintic, and molluscidal properties |
|
| Hevein |
| Cys rich; 4/5/3 disulfide bridges; Gly rich | The structure is folded into a series of loops all linked together by four disulfide bonds | Antimicrobial, antifungal activities |
|
| Daptomycin |
| 13 aa res; cyclic lipopeptide; Contains two non-proteinogenic amino acids: L-kynurenine (Kyn) and L-3-methylglutamic acid (mGlu) | Consists of 13 amino acids, 10 of which are arranged in a cyclic fashion | Gram-positive bacteria |
|
| Natural antimicrobial peptides rich in W, P, H, G | |||||
| Histatin 1 | Human saliva | 38 aa res; Sequence: DSHEKRHHGYRRKFHEKHHSHREFPFYGDYGSNYLYDN | - | Antifungal activity against |
|
| Histatin 3 | Human saliva | 32 aa res; Sequence: DSHAKRHHGYKRKFHEKHHSHRGYRSNYLYDN | - | Antifungal activity against |
|
| Histatin 5 | Human submandibular and parotid glands | 24 aa res; Cationic; His rich; Sequence: DSHAKRHHGYKRKFHEKHHSHRGY | α-helical in non-aqueous solvents | Virucidal, antifungal against |
|
| KDAMP | Humans | 19 aa res; Gly rich; Sequence: RAIGGGLSSVGGGSSTIKY | Coil structure with low α-helical content | Active aginast gram-negative bacteria, e.g. |
|
| Human lactoferricin (LfcinH) | Humans | 49 aa res; Cationic; Trp rich | Shows a helical content from Gln14 to Lys29 in the membrane mimetic solvent but a nonexistent β-sheet character in either the N- or C-terminal regions of the peptide | Antifungal |
|
| Bovine lactoferricin (LfcinB) | Bovine | 25 aa res; cationic; Trp rich | Distorted antiparallel β sheet | Inhibits the growth of a large variety of bacteria, fungi, viruses, parasites |
|
| Puroindolins | Plants, wheat grain | Cationic; Trp rich | α-Helical | Antibacterial and antifungal | Blochet et al., 1991 |
| Lebocins | Silkworm | 32 aa res; Pro rich; O-glycosylated; Sequence of lebocin 1: DLRFLYPRGKLPVPTPPPFNPKPIYIDMGNRY-NH2. The primary sequence of lebocins 1 and 2 differ only in their sugar moiety. Lebocin 3 has the same sequence as lebocin 2, except that aa res 16 is Leu instead of Pro | - | Active against gram-negative and gram-positive bacteria, antifungal |
|
| Drosocin |
| 19 aa res; Pro rich; O-glycosylated; Sequence: GKPRPYSPRPTSHPRPIRV-NH2 | β-turns | Binds bacterial DnaK, ribosomes |
|
| Pyrrhocoricin |
| 20 aa res; cyclic; Trp rich; Sequence: VDKGSYLPRPTPPRPIYNRN-NH2 | α,β-mixed structure | Binds bacterial DnaK, transduces cell membrane of parasite cryptosporidium parvum |
|
| Metchnikowin |
| 26 aa res; Trp rich | α,β-mixed structure | Gram-positive bacteria, antifungal |
|
| Calcitermin C | Human airways | 15 aa res; Sequence: VAIALKAAHYHTHKE | α-helical | Gram-negative bacteria |
|
| Attacins |
| Attacins A-D:190 aa res, Gly rich, basic; Attacins E-F: 190 aa res, Glycine rich, acidic | Attacins adopt a random coil secondary structure in an aqueous buffer | Gram-negative bacteria |
|
| Diptericins | Insects; first isolated from the blowfly | Gly rich; Mol wt.: 8–9 kDa | High β-turn content | Gram-negative bacteria |
|
| Persulcatusin |
| Cationic; Gly rich; Three S-S bonds Sequence: GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR-NH2 | α,β-mixed structure | MSSA and (MRSA) |
|
FIGURE 2Examples of natural cationic AMPs. (A) Jelleine −1. (B) Magainin.
FIGURE 3Examples of natural cyclic AMPs. (A) Valinomycin. (B) Alpha-Amanitin. (C) Gramicidin S. (D) Polymyxin B. (E) Iturin A. (F) Surfactin C.
FIGURE 4Different modes of cyclization in cyclic AMPs. (A) Homodectic cyclic peptides (head-to-tail cyclized): Guangomide A. (B) Heterodectic cyclic peptide (head/tail-to-side chain or side chain-to-side chain cyclized): Coibamide A. (C) Complex cyclic peptide: Triostin A.
FIGURE 5Examples of natural AMPs rich in Pro and Trp amino acid residues. (A) Pro rich AMP: Pyrrhocoricin. (B) Trp rich AMP: Indolicine.
Antimicrobial peptides: delivery vehicles, peptide hydrogels and peptide-nanoparticle conjugates.
| Name of the peptides | Sequence of the peptides | Physiochemical properties | Mechanism of action | Target microbes | References |
|---|---|---|---|---|---|
| - | FF | 2 aa res | Membrane permeation and depolarization |
|
|
| Fmoc-peptides | FmocFF, FmocFFKK, FmocFFFKK, FmocFFOO | - | - |
|
|
| C16-P3R | C16-PRRR-NH2 | 4 aa res; +3 net charge; Arg rich (75%) | - |
|
|
| Double chain lipopeptide | (C10)2Dap-KKK-NH2 Dap—Diaminopimelic acid | 4 aa res; +3 net charge; Lys rich (75%) | - |
|
|
| MAX1 | VKVKVKVKVDPPTKVKVKVKV-NH2 | 20 aa res; +9 net charge; Val rich (40%), Lys rich (45%) | - |
|
|
| MARG1 | VKVKVRVKVDPPTKVKVRVKV-NH2 | 20 aa res; +9 net charge; Val rich (45%), Lys rich (30%) | - |
|
|
| PEP6R | VKVRVRVRVDPPTRVRVRVKV-NH2 | 20 aa res; +9 net charge; Val rich (45%), Arg rich (30%) | Membranolytic |
|
|
| CASP-K6 | K6(SL)6K6 | 24 aa res; +12 net charge; Lys rich (50%), Ser rich (25%), Leu rich (25%) | Membrane disruption |
|
|
| WK3 (QL)6K2 | CH3CO-WKKKQLQLQLQLQLQLKK-CONH2 | 18 aa res; +5 net charge; Leu rich (33%), Gln rich (33%), Lys rich (28%) | - |
|
|
| P5 | H2N-(CH2)5-CONH-Phe-CONHC12 | - | - |
|
|
| P1 | Boc-AUDA-Phe-COOH, (AUDA = 11-aminoundecanoic Acid) | - | - |
|
|
| PAF26 | Ac-RKKWFW-NH2 | 6 aa res; +3 net charge; Trp rich (33%), Lys rich (33%) | Interaction of the peptide hydrogel with microbial cell wall |
|
|
| CG3R6TAT nanoparticles | Cholesteryl chloroformate grafted onto the N-terminus of the G3R6TAT (GGGRRRRRRYGRKKRRQRRR), TAT: YGRKKRRQRRR | - | Inhibition of cell wall synthesis; damage to the cell wall; membrane destabilization |
|
|
| G3R6-TAT functionalized colloid siver-nanoparticles (Ag-pep) | G3R6TAT (GGGRRRRRRYGRKKRRQRRR), TAT: YGRKKRRQRRR funtionalized with silver nanoparticles | - | - |
|
|
| AgNP-OA1 conjugate | Silver nanoparticles functionalized with OA1 (VVKCSYRLGSPDSQCN) | - | Predominantly secondary mechanisms such as interactions with the DNA, followed by other mechanisms that arrest the transcription and translation pathways |
|
|
| Cecropin Melittin (CM)-NPs | Fe3O4 (SPION)@gold core-shell nanoparticles functionalized with Cecropin Melittin (CM) (KWKLFKKIGAVLKVLC) | Partially membranolytic | - |
|
|
| PA-1-AgNPs | Silver nanoparticles functionalized with peptide PA-1 [Ac-NH-E (NH-CH2-CHO)-EEEAAAVVVK(C16)-CONH2] | - | - |
|
|
| Peptide-AuNPs-alginate bio-hydrogel | AuNP-alginate solution functionalized with peptide solution Nisin (ITSISLCTPGCKTGALMGCNMKTATCHCSIHVSK) | - | - |
|
|
Synthetic antimicrobial peptides (aa = amino acid, res = residues).
| Name of the peptides | Sequence of the peptides | Physiochemical properties | Mechanism of action | Target microbes | References | |
|---|---|---|---|---|---|---|
| Synthetic cationic antimicrobial peptides | ||||||
| (KIGAKI)3-NH2 | KIGAKIKIGAKIKIGAKI-NH2 | 18 aa res; +7 net charge; Lys rich (33%) | Membranolytic; Intracellular mode of actions expected as well |
|
| |
| V681n | KWKSFLKTFKSAVKTVLHTALKAISS | 26 aa res; +6 net charge; Lys rich (23%) | Possibly membranolytic |
|
| |
| V26p | KWKSFLKKLTSAAKKVLTTALKPISS | 26 aa res; +7 net charge; Lys rich (27%) | Possibly stimulation of autolytic enzymes, interference with bacterial DNA and/or inhibition of protein synthesis |
|
| |
| JH8194 | KRLFRRWQWRMKKY | 14 aa res; +7 net charge; Arg rich (29%), Lys rich (21%) | - |
|
| |
| D8R8 (Dendrimer R8) | (RLYRKVYG)2-[(K2K)2K] (Dendrimeric R8) | 64 aa res; +24 net charge; Arg rich (25%) | Membranolytic |
|
| |
| Peptide 20 | [(2-Cl-Z)-K-(HCl)]2-KF-NH(CH2)11CH3 | Lys rich | Inhibition of the activity of candidal β-(1,3)-glucan synthase, a membrane-located enzyme |
|
| |
| Esculentin-1b (1–18) | GIFSKLAGKKLKNLLISGL-NH2 | 19 aa res; +5 net charge; Lys rich (21%) | Membranolytic |
|
| |
| Esculentin-1a (1–21) | GIFSKLAGKKIKNLLISGLKG-NH2 | 21 aa res; +6 net charge; Lys rich (23%) | Membrane permeabilization |
|
| |
| (Aib1,10,18)-Esc (1–21) | Aib-IFSKLAGK-Aib-IKNLLIS-Aib-LKG-NH2 | 21 aa res; +5 net charge; Lys rich (19%) | - |
|
| |
| C12-fXXL | C11-CO-DPhe-Dab-Dab-Leu-NH2 (Dab - Diaminobutyric acid) | 4 aa res; +2 net charge; Dab rich (50%) | Membranolytic |
|
| |
| 003c | Gpp-Bip-Gpp | 3 aa res; +3 net charge | - |
|
| |
| Peptide 3 | R-Bip-R-NHBn | 3 aa res; +3 net charge; Arg rich (66%) | - |
|
| |
| TAL L512 | NH2-FLPLLGRVLSGLL-CONH2 | 13 aa res; +2 net charge; Leu rich (46%) | - |
|
| |
| S8 | C7H15-CO-dgF-K-dgF-K-NH2 | 4 aa res; + 2 net charge; dgPhe rich (50%), Leu rich (50%) | Disruption of outer and inner membranes |
|
| |
| (KLAKKLA)3 | KLAKKLAKLAKKLAKLAKKLA | 21 aa res; +9 net charge; Lys rich (43%); Leu rich (29%) | - |
|
| |
| HPA3NT3-analog | FKKLKKLFKKILKLK-NH2 | 15 aa res; +9 net charge; Lys rich (53%) | Membranolytic |
|
| |
| Peptide 3 | KW-K(Me3)-LFKKIGAVLKVL-NH2 | 15 aa res; +5 net charge; Lys rich (33%) | Membrane permeation |
|
| |
| H-DS-5W | H-KXAKWXKKXAKAXAK-NH2 (cross-linked by two oct-4-enyl staples, each represented by two X-X, three amino acids apart) | 11 aa res; +7 net charge; Lys rich (55%) | - |
|
| |
| P4 | LKWLKKL-NH2 | 7 aa res; +4 net charge; Lys rich (43%), Leu rich (43%) | Membranolytic |
|
| |
| AMP 22 | LRKVWRWLRRL-NH2 | 11 aa res; +6 net charge; Arg rich (36%) | Membrane perturbation as well as intracellular secondary mode of action |
|
| |
| VV-14 | VKWVKKVVKWVKKV-NH2 | 14 aa res; +7 net charge; Val rich (43%), Lys rich (43%) | Membrane deformation, depolarization, and lysis |
|
| |
| Triblock amphiphilic peptide (K3F6K3) | KKKFFFFFFKKK | 12 aa res; +6 net charge; Lys rich (50%) | Membranolytic |
|
| |
| PR-9 | PFWRIRIRR-NH2 | 9 aa res; +5 net charge; Arg rich (45%) | Intracellular |
|
| |
| capA6R | CH3-CONH-A6R-NH2 | 7 aa res; +1 net charge; Ala rich (86%) | Membranolytic |
|
| |
| C12-SC4 | C12-KLFKRHLKWKII-NH2 | 12 aa res; +5 net charge; Lys rich (33%) | Destabilization of bacterial membranes |
|
| |
| NB-119–2 | C16-(α-AA)5-NH2 | 5 aa res; +5 net charge | Membranolytic |
|
| |
| N-C8 | (C8-K)-RWRWRW-NH2 | 7 aa res; +4 net charge; Arg rich (43%), Trp rich (43%) | - |
|
| |
| Ano- D4,7–7C10 | GLLkRIk(C10)TLL-NH2 (Small letters indicate D-amino acids) | 10 aa res; +4 net charge; Leu rich (50%) | Membranolytic as well as intracellular |
|
| |
| Peptide 79 | KL-Tic-Oic-KG-Tic-Oic-FG-Tic-Oic-KG-Tic-Oic-FG-Tic-Oic-KG-Tic-Oic-KKKK-NH2 | 28 aa res; +9 net charge; Lys rich (29%), Tic rich (18%), Oic rich (22%) | - |
|
| |
| Cbf-14-2 | RLLR-Orn-FFR-Orn-LKK-SV-NH2 (Orn) | 14 aa res; +7 net charge; Arg rich (22%) | Membranolytic |
|
| |
| (RW)4D | Dendrimeric peptide with four RW units | Arg and Trp rich | Membranolytic |
|
| |
| Antimicrobial β-peptide | H-(β3- HVal-β3-HLys-β3-HLeu)4-OH | β aa res containing peptides | Membranolytic |
| Liu et al., 2001 | |
| Synthetic cyclic peptides | ||||||
| (Gly6)ccTP | (K | 18 aa res; +6 net charge; Gly rich (39%) | Membranolytic |
|
| |
| (R4W4) | - | 8 aa res; +4 net charge; Trp rich (50%), Arg rich (50%) | - |
|
| |
| C12-(R5) | Dodecanoyl-(KRRRRR) | 6 aa res; +5 net charge; Arg rich (83%) | - |
|
| |
| RH 11 | NH2-(CwWkKkKkWwC)-CONH2 | 11 aa res; +6 net charge; Lys rich (45%) | Membranolytic |
|
| |
| Peptide 4 | (kQrWlWlW) (Small letters represents D-amino acids) | 8 aa res; +2 net charge; Trp rich (38%) | - |
|
| |
| Peptide 7 | (WlWkUkSk) U = Ser(α-Mannose) (Small letters represent D-amino acids) | 8 aa res; +3 net charge; glycosylated | - |
|
| |
| Synthetic antimicrobial peptides rich in W, P, H, G | ||||||
| PEP 6 | frlkfh (all D amino acids) | 6 aa res; +2 net charge | Membranolytic |
|
| |
| PAF 26 | Ac-rkkwfw-NH2 (Small letters represent D-amino acids) | 6 aa res; +3 net charge; Lys rich (33%), Trp rich (33%) | - |
|
| |
| Active center of Lactoferricin B | RRWQWR-NH2 | 6 aa res; +4 charge; Arg rich (50%), Trp rich (33%) | Membranolytic |
|
| |
| KCM 21 | KWWWRW-NH2 | 6 aa res; +3 net charge; Trp rich (67%) | - |
|
| |
| (RW)3 | RWRWRW-NH2 | 6 aa res; +4 net charge; Trp rich (50%), Arg rich (50%) | Membranolytic |
|
| |
| GSP-5D | MPLSWFFPRTWGKR-NH2 | 14 aa res; +4 net charge | - |
|
| |
| GA-K4AL | FAKWAFKWLKK-NH2 | 11 aa res; +5 net charge; Lys rich (36%) | - |
|
| |
| PW2 | HPLKQYWWRPSI | 12 aa res; +2 net charge | - |
|
| |
| CP-11 | ILKKWPWWPWRRK-NH2 | 13 aa res; +6 net charge; Trp rich (30%), Lys rich (23%) | Both membranolytic and intracellular |
|
| |
| CycloCP-11 | ICLKKWPWWPWRRCK-NH2 (Cyclized through S-S cys bonds at the temini) | 15 aa res; +6 net charge; Trp rich (27%), Lys rich (20%) | Both membranolytic and intracellular |
|
| |
| CP-11C | ILKKWPWWPWRRK-OMe | 13 aa res; +5 net charge; Trp rich (30%), Lys rich (23%) | Membranolytic |
|
| |
| RN7-IN10 | FLGGLIKWKWPWWPWRR-NH2 | 17 aa res; +5 net charge; Trp rich (29%) | Membranolytic as well as inhibition of intracellular functions due to DNA binding |
|
| |
| Puro A | FPVTWRWWKWWKG-NH2 | 13 aa res; +4 net charge; Trp rich (38%) | Membranolytic |
|
| |
| PR 26 | RRRPRPPYLPRPRPPPFFPPRLPPRI | 26 aa res; +8 net charge; Pro rich (46%), Arg rich (30%) | Membranolytic |
|
| |
| Bac5 (1–25) | RFRPPIRRPPIRPPFYPPFRPPIRP | 25 aa res; +7 net charge; Pro rich (44%), Arg rich (28%) | Intracellular and nonlytic mode of action |
|
| |
| GKH17-WWWWW | GKHKNKGKKNGKHNGWKWWWWW | 22 aa res; +7 net charge; Lys rich (32%), Trp rich (27%), Gly rich (18%) | Membranolytic |
|
| |
| PS1-5 | (RWYR)3-HN2 | 12 aa res; +7 net charge, Arg rich (50%) | Membranolytic |
|
| |
| 4HarHHC-10 | Har-Har-Trp-Trp-Har-Trp-Ile-Har-Trp-NH2 (Har: L-homoarginine) | 9 aa res; +5 net charge; Trp rich (44%), Har rich (44%) | Membranolytic |
|
| |
| 12b | Dendrimeric (WRW)3 | Dendrimeric, trivalent; 3 aa res; +3 net charge; Trp rich (67%), Arg rich (33%) | Membranolytic |
|
| |
| - | RWRWRWA-(Bpa) | 7 aa res; +4 net charge; Trp rich (42%), Arg rich (42%) | - |
|
| |
| KU 2 | GIWKKWIKKWLNVLKNLF-NH2 | 18 aa res; +5 net charge; Lys rich (28%) | - |
|
| |
| P6 (Modified PMAP-23) | RIIDLLWRVWRPWWPKFVTVWVR-NH2 | 23 aa res; +5 net charge; Trp rich (22%) | Membranolytic |
|
| |
| RV-23 | RIGVLLARLPKLFSLFKLMGKKV-NH2 | 23 aa res; +7 net charge; Lys rich (18%) | Membranolytic |
|
| |
| Di-K19Hc | (KWLNALLHHGLNCAKGVLA)2 (Dimerized through Cys) | 38 aa res; +6 net charge | Membranolytic |
|
| |
| (D)-K5L7-UA | KKllKLLlKlLK-NHCO-(CH2)9-CH3 (Small letters signify D-amino acids) | 12 aa res; +5 net charge; Leu rich (58%), Lys rich (42%) | Membranolytic |
|
| |
| P0-1 | GIKKWLHSAKKFGKKFVKKIMNS-NH2 | 23 aa res; +9 net charge; Lys rich (35%) | Membrane permeabili-zation and DNA binding |
|
| |
FIGURE 6Examples of synthetic cationic AMPs. (A) VV-14 (Pandit et al., 2020). (B) Dendrimeric peptide: (RW)4D (Hou et al., 2009). (C) C12-SC4 (Chu-Kung et al., 2004).
FIGURE 7Examples of synthetic cationic AMPs containing unnatural amino acid residues. (A) Cbf-14–2 (Kang et al., 2017). (B) NB-119–2 (Hu et al., 2012). (C) β-amino acid containing peptide H-(β3-H-Val- β3-H-Lys- β3-H-Leu)4-OH (Liu and De Grado, 2001).
FIGURE 8Examples of synthetic cyclic AMPs. (A) (R4W4) (Oh et al., 2014). (B) C12-R5 (Oh et al., 2014). (C) (kQrWlWlW) (Fernandez-Lopez et al., 2001). (D) (WlWkUkSk), U = Ser(α-Man) (Motiei et al., 2009).
FIGURE 9Examples of synthetic AMPs rich in specific amino acid residues (Trp, Pro, His and Gly). (A) Trp-Pro rich peptide: RN7-IN10 (Jindal et al., 2017). (B) Trp-Gly rich peptide: GKH17WWWWW (Pasupuleti et al., 2009).
FIGURE 10AMPs forming hydrogels. (A) PAF26 (Cao et al., 2019). (B) Boc-AUDA-Phe-COOH (P1), (AUDA = 11-aminoundecanoic acid) (Baral et al., 2016). (C) H2N-(CH2)5-CONH-Phe-CONH-C12 (P5) (Nandi et al., 2017).
FIGURE 11Schematic of (A) Stepwise synthesis of AMP-AuNP conjugates and (B) Formation of AMP-NP conjugates and their action on lipid membrane of the microbes.